
PF-06260414
An experimental SARM for muscle failure research has entered Phase I clinical trials.
概况
PF-06260414 is an oral nonsteroidal SARM with potent anabolic effects in muscle, targeting sarcopenia and muscle decline in early clinical trials. It enhances muscle mass, strength, and bone health with tissue-specific benefits and fewer side effects than steroids. Used in sports nutrition research and age-related muscle wasting studies.
Synonyms: PF6260414; PF-6260414; 1-Isoquinolinecarbonitrile,6-[(4R)-tetrahydro-4-methyl-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl]-; PF-06260414>=98%(HPLC); 6-((4R)-4-Methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile
Product Categories: SARM series
Mol File: 1612755-71-1.mol
物化性质
Boiling point: 539.7±53.0°C(Predicted)
Density: 1.45±0.1g/cm3(Predicted)
Storage temp.: room temp
Solubility: DMSO: 5mg/mL, clear (warmed)
Form: powder
Color: light orange to dark orange
MSDS信息
实验数据
Pharmacodynamics
Mechanism Of Action
相似产品

GSK-2881078
治疗领域
: Musculoskeletal diseases
作用靶点
: AR
CAS
: 1539314-06-1
分子式
: C14H13F3N2O2S
分子量
: 330.33

MK-0773
治疗领域
: Musculoskeletal diseases
作用靶点
: AR
CAS
: 606101-58-0
分子式
: C27H34FN5O2
分子量
: 479.59

MK-4541
治疗领域
: Musculoskeletal diseases
作用靶点
:
CAS
: 796885-38-6
分子式
: C22H31F3N2O3
分子量
: 428.49

LGD-2226
治疗领域
: Musculoskeletal diseases
作用靶点
:
CAS
: 328947-93-9
分子式
: C14H9F9N2O
分子量
: 392.22
